Dong Hyun Seo

Dong Hyun Seo

Auto-generated profile, based on publicly available information

Dong Hyun Seo

Department of Internal Medicine, Open NBI Convergence Technology Research Laboratory, Yonsei University College of Medicine, Seoul 03722, South Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Clinical and Translational Medicine
Verified
Journal Article
Open access
DSDong Hyun Seo
Dong Hyun Seo
SLSeul Gi Lee
Seul Gi Lee
HLHwa Young Lee
Hwa Young Lee
SJSeonhyang Jeong
Seonhyang Jeong
SPSunmi Park
Sunmi Park
YJYoung Suk Jo
Young Suk Jo

4 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
SLSunyoung S. Lee
Sunyoung S. Lee
DSDong Hyun Seo
Dong Hyun Seo
TCTaek Chung
Taek Chung
DFDaniel Fox
Daniel Fox
JHJaime Ivan Haro-Silerio
Jaime Ivan Haro-Silerio
CLChoong-Kun Lee
Choong-Kun Lee
Purpose: This study aimed to evaluate the prognostic relevance of HER2 positivity and the clinical impact of anti-HER2 therapy in the management of advanced biliary tract cancers using integrated multi-institutional data. Experimental Design: This retrospective analysis included 388 patients with advanced biliary tract cancers and known HER2 status from Yonsei Cancer Center and MD Anderson Cancer Center between 2009 and 2023. HER2 positivity was defined as HER2 IHC 3+, IHC 2+ with in situ hybridization positivity, or ERBB2 amplification by next-generation sequencing. Clinical outcomes, including survival, and genomic profiling with curated oncogenic pathway enrichment were analyzed. Results: HER2 positivity was observed in 25.2% of the epidemiology analysis cohort (n = 309). In the survival analysis (n = 310), HER2-positive biliary tract cancers were associated with shorter overall survival [(OS); 13.7 vs. 17.1 months; HR, 1.25; 95% confidence interval (CI), 0.97–1.60] and significantly shorter first-line progression-free survival (5.1 vs. 7.4 months; HR, 1.91; 95% CI, 1.46–2.48) than HER2-negative biliary tract cancers. Anti-HER2 therapy significantly improved OS among HER2-positive patients (18.2 vs. 8.1 months; HR, 0.39; 95% CI, 0.21–0.62). Genomic analysis showed the strongest enrichment of angiogenesis pathway alterations in HER2-positive patients, whereas KRAS mutations were predominant in HER2-negative biliary tract cancers. Conclusions: HER2 is a clinically meaningful biomarker with prognostic and predictive relevance in advanced biliary tract cancers. Anti-HER2 therapy significantly improves survival in HER2-positive patients. These findings support routine HER2 testing, standardization of HER2 diagnostic criteria, and further prospective evaluation of HER2-targeted strategies for biliary tract cancers.

29 August 2025 in Science Advances
Verified
Journal Article
Open access
DSDong Hyun Seo
Dong Hyun Seo
ELEunjung Lee
Eunjung Lee
JYJung Hyun Yoon
Jung Hyun Yoon
EPEun Gyeong Park
Eun Gyeong Park
SPsunmi park
sunmi park
YJYoung Suk Jo
Young Suk Jo
Papillary thyroid carcinoma (PTC) generally has a favorable prognosis; however, overtreatment persists because of the lack of reliable noninvasive risk stratification tools. This study developed a radiomics-based approach to enhance the preoperative assessment of PTC. Imaging features from 255 patients were analyzed, and three tumor clusters were identified via unsupervised clustering, with one cluster (Cluster 2) displaying favorable clinical and molecular profiles. A radiomics score was constructed and validated internally and externally, achieving high diagnostic accuracy (area under the curve of 0.98) and independently predicting benign features such as a lower N stage and favorable treatment responses. Transcriptomic analysis revealed immune activation and survival-related gene expression in Cluster 2. The model demonstrated robust performance in stratifying patients for active surveillance and may complement current diagnostic frameworks, offering a precise, noninvasive tool to guide clinical decision-making.

18 November 2025 in eClinicalMedicine
Verified
Journal Article
Open access
CLChoong-Kun Lee
Choong-Kun Lee
IKIlwhan Kim
Ilwhan Kim
DSDong Hyun Seo
Dong Hyun Seo
SPSejung Park
Sejung Park
MKMinjae Kim
Minjae Kim
HCHye Jin Choi
Hye Jin Choi
FOLFIRINOX treatment for pancreatic cancer often causes severe neutropenia, leading to dose reductions and potentially fatal outcomes. Despite this, high-level evidence supporting pegylated granulocyte colony-stimulating factor (peg-GCSF) as the primary prophylaxis is lacking. This study aimed to determine whether primary prophylaxis of peg-GCSF can prevent severe neutropenia in patients with pancreatic cancer treated with modified-(m)FOLFIRINOX. This was an investigator-initiated, open-label, multi-institutional, randomized phase 2 trial in patients aged ≥19 years with treatment-naïve locally advanced or metastatic pancreatic cancer. Patients received oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2, and fluorouracil 2400 mg/m2 via continuous infusion, every other week. After 1:1 randomization, peg-GCSF (pegteograstim 6 mg, GC Biopharma Corp.) was subcutaneously administered on day 4 for the initial eight cycles for the primary prophylaxis group, whereas no G-CSF was given to the control group. Crossover to administering peg-GCSF was permitted if patients in the control group developed grade 3–4 neutropenia during the initial eight cycles. Co-primary endpoints were grade 3–4 neutropenia or febrile neutropenia within the first eight cycles. Secondary endpoints included survival, relative dose intensity, patient-reported quality of life (QOL), and bone pain. This trial is registered with the CRIS (KCT0006536) and ClinicalTrials.gov (NCT06353581). Seventy-seven patients were enrolled from February 2022 to January 2024, with 38 in the peg-GCSF primary prophylaxis group and 39 in the control group. The primary endpoints were achieved, with significantly lower grade 3–4 neutropenia in the peg-GCSF group (2.6% vs. 38.5%, P = 0.0001) compared to the control group, and febrile neutropenia occurring only in controls (12.8%). With a median follow-up duration of 19.7 months, survival outcomes favored peg-GCSF, although not statistically significant. The adjusted mean change of global health status or QOL scores were significantly higher for the peg-GCSF primary prophylaxis group than for the control group (P = 0.0264), without an increase in reported bone pain. Survival, QOL, and bone pain were secondary endpoints. Peg-GCSF primary prophylaxis significantly reduced grade 3–4 neutropenia and febrile neutropenia in patients with locally advanced or metastatic pancreatic cancer treated with mFOLFIRINOX. Peg-GCSF primary prophylaxis also provided a numerical survival benefit with better patient-reported QOL. This study provides a rationale for peg-GCSF primary prophylaxis in patients with pancreatic cancer treated with mFOLFIRINOX. GC Biopharma Corp.; Severance Hospital Research Fund for Clinical Excellence; 10.13039/501100003725 National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT).


10 October 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
DSDong Hyun Seo
Dong Hyun Seo
YJYeongjun Jeon
Yeongjun Jeon
EPEun Gyeong Park
Eun Gyeong Park
SYSongyi Yang
Songyi Yang
SPSunmi Park
Sunmi Park
YJYoung Suk Jo
Young Suk Jo
COVID-19 pandemic profoundly impacted global health, yet its effects on autoimmune thyroid diseases, particularly chronic lymphocytic thyroiditis (CLT), remain unclear. We aimed to evaluate how clinical, laboratory, and radiological features of CLT changed across distinct phases of the pandemic. In this single-institutional retrospective study, we included 7717 patients who underwent thyroidectomy with histologically confirmed CLT from January 2015 to August 2024, excluding those with concurrent autoimmune diseases or incomplete clinical data. Patients' data were stratified into pre-pandemic (before January 2020), pandemic (January 2020-October 2021), and post-pandemic (after October 2021) periods. Demographics, thyroid function tests, autoantibody titers (thyroid peroxidase antibody [TPOAb] and thyroglobulin antibody [TgAb]), ultrasonographic features, and thyroid hormone dosages were compared. Predictors for disease-related outcomes were identified using monthly aggregated interrupted time series analyses. Age distribution was consistent among groups, but the proportion of female sex significantly decreased (90.0 % pre-pandemic, 87.0 % post-pandemic; p < 0.001) and body mass index increased (23.3 ± 3.5 kg/m2 pre-pandemic, 23.6 ± 3.3 kg/m2 post-pandemic; p < 0.001). TPOAb levels were significantly elevated during the pandemic (145.6 ± 275.6 IU/mL) and post-pandemic periods (172.4 ± 273.4 IU/mL) compared to pre-pandemic levels (103.5 ± 270 IU/mL, p < 0.001). TgAb levels were predominantly elevated during the pandemic period (320.4 ± 548.9 vs. 242.8 ± 585 IU/mL pre-pandemic, p < 0.001). Ultrasound features suggestive of CLT, autoantibody positivity and elevated TSH levels were all significantly associated with an increased prevalence after the pandemic (p < 0.05). The COVID-19 pandemic significantly influenced CLT characteristics, including altered autoantibody profiles, radiological manifestations, and increased thyroid hormone requirements. Therefore, consideration of pandemic-driven changes during patient management is urged.